Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic-Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104.

Yates, James W T; Ashton, Susan; Cross, Darren; Mellor, Martine J; Powell, Steve J; Ballard, Peter

Yates, James W T; Ashton, Susan; Cross, Darren; Mellor, Martine J; Powell, Steve J; Ballard, Peter.

Affiliation

Yates JW; Oncology DMPK, AstraZeneca, Cambridge and Alderley Park, Macclesfield, United Kingdom. James.Yates@astrazeneca.com.
Ashton S; Oncology Biosciences, AstraZeneca, Cambridge and Alderley Park, Macclesfield, United Kingdom.
Cross D; Oncology Biosciences, AstraZeneca, Cambridge and Alderley Park, Macclesfield, United Kingdom.
Mellor MJ; Oncology Biosciences, AstraZeneca, Cambridge and Alderley Park, Macclesfield, United Kingdom.
Powell SJ; Oncology Biosciences, AstraZeneca, Cambridge and Alderley Park, Macclesfield, United Kingdom.
Ballard P; Oncology DMPK, AstraZeneca, Cambridge and Alderley Park, Macclesfield, United Kingdom.

Mol Cancer Ther ; 15(10): 2378-2387, 2016 10.

Article in En | MEDLINE | ID: mdl-27439477

Subject(s)

Antineoplastic Agents/pharmacokinetics; ErbB Receptors/antagonists & inhibitors; Piperazines/pharmacology; Protein Kinase Inhibitors/pharmacokinetics; Acrylamides; Algorithms; Aniline Compounds; Animals; Antineoplastic Agents/chemistry; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors/chemistry; Humans; Mice; Models, Biological; Piperazines/chemistry; Protein Kinase Inhibitors/chemistry; Xenograft Model Antitumor Assays

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Protein Kinase Inhibitors / ErbB Receptors / Antineoplastic Agents Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Mol Cancer Ther Journal subject: ANTINEOPLASICOS Year: 2016 Document type: Article Affiliation country: United kingdom Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links